Clinical consequences of pharmacokinetic properties of cardiac glycosides
Kochsiek, K.
European Heart Journal 3 Suppl D: 79-86
1982
ISSN/ISBN: 0195-668X PMID: 6761130 Document Number: 187182
Document emailed within 1 workday
Related Documents
Synek, P. 1989: The past and present of cardiac glycosides. II. Structure, physical and chemical properties. Pharmacodynamics Casopis Lekaru Ceskych 128(4): 121-127Dayer, P.; Courvoisier, F.; Kupfer, A.; Balant-Gorgia, A.; Balant, L.; Fabre, J. 1983: Pharmacokinetic and clinical consequences of the genetic polymorphism of oxidation Schweizerische Medizinische Wochenschrift 113(8): 295-297
Nasonova, T.I. 1977: Evaluation of the clinical effect of treatment with cardiac glycosides under conditions of ambulatory observation Kardiologiia 17(9): 53-57
Iakovlev, V.P. 1994: Ceftizoxime--antibacterial activity, pharmacokinetic properties, clinical application Antibiotiki i Khimioterapiia 39(6): 49-62
Brogden, R.N.; Buckley, M.M.; Ward, A. 1990: Buserelin. a review of its pharmacodynamic and pharmacokinetic properties, and clinical profile Drugs 39(3): 399-437
Tromm, A.; Griga, T.; May, B. 1999: Oral mesalazine for the treatment of Crohn's disease: clinical efficacy with respect to pharmacokinetic properties Hepato-Gastroenterology 46(30): 3124-3135
Mareev, V.I.; Lopatin, I.M.; Dzhakhangirov, T.S.; Gkhani, P.; Ageev, F.T.; Belenkov, I.N. 1993: Comparative study on use of angiotensin-converting enzyme inhibitors and cardiac glycosides in the treatment of cardiac insufficiency Kardiologiia 33(12): 23-31; 3-4
Masliuk, V.I.; Popov, V.G.; Popova, T.A.; Litvintsev, V.P. 1972: Treatment of cardiac insufficiency with cardiac glycosides in a complex with preparations effecting nucleic acid synthesis and energy formation Kardiologiia 12(1): 45-52
Simon, H. 1976: Therapy with cardiac glycosides Hippokrates 47(1): 30-52
Ignat'ev, M.V. 1988: Treatment with cardiac glycosides Fel'dsher i Akusherka 53(5): 40-44
Kramer, P.; Matthias, C.; Matthaei, D.; Scheler, F. 1977: Elimination of cardiac glycosides by hemofiltration Verhandlungen der Deutschen Gesellschaft für Innere Medizin 83: 1618-1621
Kimbel, K.H. 1977: Combination of cardiac glycosides and norephedrine? Deutsche Medizinische Wochenschrift 102(10): 375
Erbel, R. 1978: Exertion ECG during therapy with cardiac glycosides Deutsche Medizinische Wochenschrift 103(14): 632
Chien, J.Y.; Thummel, K.E.; Slattery, J.T. 1997: Pharmacokinetic consequences of induction of CYP2E1 by ligand stabilization Drug Metabolism and Disposition: the Biological Fate of Chemicals 25(10): 1165-1175
Stenkvist, B.; Bengtsson, E.; Dahlqvist, B.; Eriksson, O.; Jarkrans, T.; Nordin, B. 1982: Cardiac glycosides and breast cancer, revisited New England Journal of Medicine 306(8): 484
Assmann, I.; Fiehring, H.; Schmidt, H.; Hesse, P.; Banse, P. 1971: Comparison of medium-range cardiac glycosides Das Deutsche Gesundheitswesen 26(50): 2355-2357
Godfraind, T. 1973: The therapeutic mode of action of cardiac glycosides Archives Internationales de Pharmacodynamie et de Therapie 206(2): 384-388
Golota, L.G. 1972: Effect of unithiol on the toxicity of cardiac glycosides Vrachebnoe Delo 3: 41-42
Grosse-Brockhoff, F. 1981: Therapy of cardiac insufficiency with digitalis glycosides Fortschritte der Medizin 99(18): 665-668
Kots, I.I.; Starshinova, A.E. 1973: Action of unithiol in arrhythmias not associated with intoxication with cardiac glycosides Kardiologiia 13(11): 107-109